Clinical predictors for fatal pulmonary embolism in 15 520 patients with venous thromboembolism -: Findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) registry

被引:534
作者
Laporte, Silvy [1 ]
Mismetti, Patrick [1 ,2 ]
Decousus, Herve [1 ,3 ]
Uresandi, Fernando [4 ]
Otero, Remedios [6 ]
Lobo, Jose Luis [5 ]
Monreal, Manuel [7 ]
机构
[1] Univ Hosp St Etienne Bellevue, Dept Clin Pharmacol, Thrombosis Res Grp, EA 3065, F-42055 St Etienne 02, France
[2] Univ Hosp, Dept Internal Med, F-42055 St Etienne, France
[3] CIE3, INSERM, F-42055 St Etienne, France
[4] Hosp Cruces, Dept Pulmonol, Baracaldo, Vizcaya, Spain
[5] Hosp Txagorritxu, Dept Pulmonol, Victoria, Alava, Spain
[6] Hosp Virgen Rocio, Dept Pulmonol, Seville, Spain
[7] Hosp Badalona Germans Trias & Pujol, Dept Internal Med, Badalona, Spain
关键词
death; sudden; prognosis; pulmonary embolism; thrombosis;
D O I
10.1161/CIRCULATIONAHA.107.726232
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Clinical predictors for fatal pulmonary embolism (PE) in patients with venous thromboembolism have never been studied. Methods and Results - Using data from the international prospective Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) registry about patients with objectively confirmed symptomatic acute venous thromboembolism, we determined independent predictive factors for fatal PE. Between March 2001 and July 2006, 15 520 consecutive patients (mean age +/- SD, 66.3 +/- 16.9 years; 49.7% men) with acute venous thromboembolism were included. Symptomatic deep-vein thrombosis without symptomatic PE was observed in 58.0% (n = 9008) of patients, symptomatic nonmassive PE in 40.4% (n = 6264), and symptomatic massive PE in 1.6% (n = 248). At 3 months, the cumulative rates of overall mortality and fatal PE were 8.65% and 1.68%, respectively. On multivariable analysis, patients with symptomatic nonmassive PE at presentation exhibited a 5.42-fold higher risk of fatal PE compared with patients with deep-vein thrombosis without symptomatic PE (P < 0.001). The risk of fatal PE was multiplied by 17.5 in patients presenting with a symptomatic massive PE. Other clinical factors independently associated with an increased risk of fatal PE were immobilization for neurological disease, age >75 years, and cancer. Conclusion - PE remains a potentially fatal disease. The clinical predictors identified in the present study should be included in any clinical risk stratification scheme to optimally adapt the treatment of PE to the risk of the fatal outcome.
引用
收藏
页码:1711 / 1716
页数:6
相关论文
共 34 条
[1]   Fatal pulmonary embolism in hospitalised patients: a necropsy review [J].
Alikhan, R ;
Peters, F ;
Wilmott, R ;
Cohen, AT .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (12) :1254-1257
[2]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[3]   A prediction rule to identify low-risk patients with pulmonary embolism [J].
Aujesky, D ;
Obrosky, DS ;
Stone, RA ;
Auble, TE ;
Perrier, A ;
Cornuz, J ;
Roy, PM ;
Fine, MJ .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (02) :169-175
[4]   Antithrombotic therapy for venous thromboembolic disease [J].
Büller, HR ;
Agnelli, G ;
Hull, RD ;
Hyers, TA ;
Prins, AH ;
Raskob, GE .
CHEST, 2004, 126 (03) :401S-428S
[5]   Fondaparinux or Enoxaparin for the initial treatment of symptomatic deep venous thrombosis -: A randomized trial [J].
Büller, HR ;
Davidson, BL ;
Decousus, H ;
Gallus, A ;
Gent, M ;
Piovella, F ;
Prins, MH ;
Raskob, G ;
Segers, AEM ;
Cariou, R ;
Leeuwenkamp, O ;
Lensing, AWA .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (11) :867-873
[6]  
Büller HR, 2003, NEW ENGL J MED, V349, P1695
[7]   Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism - The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study [J].
Decousus, H ;
Barral, FG ;
Buchmuller-Cordier, A ;
Charbonnier, B ;
Girard, P ;
Lamer, C ;
Laporte, A ;
Leizorovicz, A ;
Mismetti, P ;
Parent, F ;
Quenet, S ;
Rivron-Guillot, K ;
Tardy, B .
CIRCULATION, 2005, 112 (03) :416-422
[8]   A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis [J].
Decousus, H ;
Leizorovicz, A ;
Parent, F ;
Page, Y ;
Tardy, B ;
Girard, P ;
Laporte, S ;
Faivre, R ;
Charbonnier, B ;
Barral, FG ;
Huet, Y ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (07) :409-415
[9]  
Douketis J D, 2001, Curr Opin Pulm Med, V7, P354, DOI 10.1097/00063198-200109000-00018
[10]   Risk of fatal pulmonary embolism in patients with treated venous thromboembolism [J].
Douketis, JD ;
Kearon, C ;
Bates, S ;
Duku, EK ;
Ginsberg, JS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (06) :458-462